NRx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued and Other Current Liabilities

9 Months Ended

Sep. 30, 2022

6. Accrued and Other Current Liabilities

Accrued and other current liabilities consisted of the following at the dates indicated (in thousands):


	September 30, 2022		December 31, 2021
	(Unaudited)
Accrued and other current liabilities:
Accrued research and development expenses	$	1,624	$	1,055
Accrued employee expenses		554		456
Professional services		264		743
Other accrued expenses		2,625		121
Total accrued and other current liabilities	$	5,067	$	2,375